Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Core Insights - Coherus Oncology, Inc. will release its third quarter 2025 financial results on November 6, 2025, after market close [1] - A conference call and webcast will be held at 5:00 p.m. Eastern Time on the same day to discuss the financial results and provide a business update [1][3] Company Overview - Coherus Oncology is a commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a growing revenue stream [6] - The company has a promising pipeline that includes two mid-stage clinical candidates targeting various cancers such as liver, lung, and head & neck [6] Pipeline and Research - Coherus' pipeline features multiple antibody immunotherapy candidates aimed at enhancing immune responses against tumors [7] - CHS-114, a selective anti-CCR8 antibody, is currently in Phase 1b/2a studies for advanced solid tumors [7] - Casdozokitug, an IL-27 antagonistic antibody, is being evaluated in a Phase 2 study for first-line hepatocellular carcinoma [7]